Patients must have high-grade bladder cancer as defined by  World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification
Neuroendocrine tumors (NETs), grade  and grade  according to World Health Organization classification.
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient must not have Burkitts lymphoma/leukemia based on the World Health Organization (WHO) criteria
Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:
Morphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteria
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria () which is relapsed or refractory after failing at least  regimen and is not a candidate for established salvage treatment regimens
Documented pathological evidence of MDS as defined by the World Health Organization (WHO) criteria
Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:
Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
Diagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the  World Health Organization classification system
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ?% bone marrow blasts based on histology or flow cytometry
Subject has documented, histologically locally confirmed, previously untreated CD+ DLBCL (NOS) per World Health Organization (WHO) classifications (Swerdlow, ).
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.
RAEB- per World Health Organization (WHO) MDS criteria (% to <% BM blasts)
Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade  or  (atypical or anaplastic)
Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.
RR DLBCL per the  World Health Organization (WHO) classification of hematopoietic and lymphoid tumors (Swerdlow et al, ).
Diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification.
Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= % blasts are also eligible at the discretion of the principal investigator
Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
Patients must have histologically confirmed ND or R/R PTCL defined according to the  World Health Organization (WHO) classification criteria, with no accepted curative options\r\n* Patients with extranodal natural killer (NK)/T-cell lymphoma may only be allocated to treatment Arm D
Histologically confirmed PTCL as defined by World Health Organization (WHO)  criteria
Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria
Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classification
AML according to world health organization (WHO) criteria (i.e. bone marrow blasts >%)
Diagnosis of AML based on  World Health Organization (WHO) criteria; AML may be de novo, following a prior hematologic disorder, including MDS or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related
Patients with World Health Organization (WHO) class III or IV pulmonary hypertension
Histologically documented diagnosis (based on the  World Health Organization [WHO] Classification) of one of the following:
Patients must have histologically or cytologically confirmed diagnosis of mycosis fungoides (MF), Sezary syndrome (SS) or primary cutaneous CD-positive lymphoproliferative disorder, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL) (pc-ALCL) as defined by the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissue
For Part  of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification  for which standard measures do not exist or are no longer effective.
Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
Diagnosis of ) AML (World Health Organization [WHO] classification definition of >= % blasts), or ) high risk MDS (defined as the presence of % blasts)
History of AML according to World Health Organization (WHO) classification
Histologic confirmation of thymic carcinoma (World Health Organization [WHO] classification)
Mature T-cell non-Hodgkin lymphoma (see World Health Organization [WHO] for specific malignancies)\r\n* First CR\r\n* Relapse after greater than or equal to  prior regimen
Diagnosis of AML (World Health Organization [WHO] classification definition of >= to % blasts)
Diagnosis of myelodysplastic syndrome (MDS) confirmed within  weeks prior to study entry according to World Health Organization (WHO) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
Histologically confirmed mantle cell lymphoma classified according to World Health Organization (WHO) criteria confirmed at MSKCC
Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria
Histologically confirmed diagnosis of World Health Organization (WHO) I-III meningiomas and hemangiopericytomas
Subjects with pathologic evidence of an anaplastic oligodendroglioma or mixed glioma (i.e. oligoastrocytoma) are eligible; histopathologic diagnosis will be made using World Health Organization classification criteria; to qualify as a mixed tumor there must be a minimum of % oligodendroglial element
Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT
Confirmed diagnosis of de novo AML according to World Health Organization (WHO)  classification
Confirmed diagnosis of AML according to World Health Organization (WHO)  classification
Histologically or cytologically documented diagnosis of MDS according to the World Health Organization (WHO) classification (Vardiman , Arber ) with >% and <% bone marrow blasts by morphology and a peripheral white blood cell (WBC) count of <,/?L
Cytologically or histologically confirmed diagnosis of MDS or CMML according to the  World Health Organization (WHO) classification.
Diagnosis of AML per World Health Organization criteria
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria () and fulfills one of the following:
Morphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria
Patients must have histologically or cytologically confirmed AML according to the World Health Organization (WHO) criteria
Histologically confirmed follicular non-Hodgkin lymphoma, World Health Organization (WHO) classification grade , , or a (>  centroblasts per high-power field with centrocytes present)\r\n* Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies\r\n* Fine-needle aspirates are not acceptable\r\n* Failure to submit pathology within  days of patient registration will be considered a major protocol violation
A diagnosis of ET or PV shall be made in accordance with the World Health Organization (WHO) () criteria (Swerdlow )
Relapsed or refractory CD-positive AML [per World Health Organization (WHO)].
Relapsed or refractory CD-positive ALL [per World Health Organization (WHO)].
Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization
Age ?  years at the time of signing the informed consent form. . Central confirmation of diagnosis of previously untreated primary or secondary Myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.
Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO)  classification
A diagnosis of SM per  World Health Organization (WHO) criteria; patients with ASM and MCL, or SM-AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria (Gotlib, )
A diagnosis of systemic mastocytosis (SM) per  World Health Organization (WHO) Criteria
Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, ] as determined by pathology review at the treating institution.
In Part , diagnosis of myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteria
Diagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders
JAKVF-positive PV or JAKVF-positive ET (confirmed by World Health Organization [WHO] diagnostic criteria)
Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).
Patients with thymic carcinoma (formerly World Health Organization [WHO] type C)
Subjects must have their diagnosis of high-risk AML or high-risk MDS confirmed by pathologic review of bone marrow biopsy according to World Health Organization (WHO) guidelines
Subjects with a histologically confirmed diagnosis of MDS by FAB criteria, including both MDS and RAEB-T (AML with -% blasts and multilineage dysplasia) by World Health Organization (WHO) classification are eligible.
Patients must have a diagnosis of CLL/SLL or B-cell prolymphocytic leukemia, as defined by the World Health Organization (WHO)
Age >= , or age >=  ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization classification
Confirmed diagnosis of CMML using the World Health Organization (WHO) classification
primary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteria
Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as defined by a B-cell neoplasm in the World Health Organization classification scheme except as noted in exclusion criteria.
Must have measurable disease by modified World Health Organization (WHO) criteria
Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO)  criteria.
Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO)  classification.
Patients must have a previous morphologically confirmed diagnosis of AML based on World Health Organization (WHO) criteria
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:
Confirmed diagnosis of AML, including treatment-related secondary AML (except prior MDS) according to World Health Organization (WHO)  classification at treating institution
Newly-diagnosed AML by World Health Organization (WHO) criteria (>= % myeloid blasts by morphology in either blood or marrow)
Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria () and fulfills one of the following:
Biopsy-proven diagnosis of cHL (regardless of Hodgkin/Reed-Stemberg [HRS] cell cluster of differentiation [CD] expression) per the World Health Organization classification criteria; lymphocyte predominant histology is excluded
The patient has a diagnosis of AML according to World Health Organization (WHO) criteria.
Have histologically or cytologically confirmed recurrent Grade  or  LGG (oligodendroglioma or astrocytoma according to World Health Organization  classification).
Diagnosis of histopathologically confirmed B-cell NHL (as per the World Health Organization [WHO]  classification) including WM/LPL.
Documentation that the participant has met the revised  World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)
. A pathologically confirmed diagnosis of AML or CMML- by World Health Organization (WHO) classification that is relapsed or refractory or for which no current therapies are anticipated to result in a durable remission, or MDS by WHO classification are RAEB- or RAEB- and that have failed at least three cycles of hypomethylating therapy, or primary (PMF), post-polycythemia vera (PPMF) or post-essential thrombocythemia (PTMF) MF by WHO classification, are high-risk category by the Dynamic International Prognostic Scoring System (DIPSS Plus), have ?% circulating blasts, and have failed treatment with ruxolitinib
Indolent NHL subtypes defined according to World Health Organization guidelines:
The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.
Patients must have had histologic verification of AML at original diagnosis; AML is defined according to World Health Organization (WHO) classification with >= % blasts in the bone marrow (M/M bone marrow), with or without extramedullary disease
Patients must have a histologically confirmed diagnosis of non-Hodgkin lymphoma (NHL); the World Health Organization (WHO) classification will be used to sub-classify the NHL; original pathology reports will be used to confirm eligibility; review of biopsy tissue slides will be attempted, but not necessary for eligibility
Diagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO) criteria
Receiving health care primarily through an health maintenance organization (HMO)
Attained menopause as defined by World Health Organization Criteria
Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO)  classification (at Screening);
Score of >=  on the World Health Organization (WHO) Alcohol Use Disorders Identification Test (AUDIT, sensitivity of .)
Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO ] classification).
